Why It Matters
Reconstructive surgery in urology and ophthalmology faces major challenges: high complication rates, long recovery times, and limited donor tissue availability. Our mission is to close this gap with a sustainable, patient-focused solution.
Urethral Strictures
More than 500,000 cases per year in EU&USA, with high recurrence rates and impaired quality of life.
LSCD & Corneal Damage
Thousands of patients suffer from severe vision loss due to damaged corneal tissue.
Aesthetic Surgery
Increasing demand for tissue grafts faces low availability and challenging harvesting techniques.
MukoCell®
We are developing a breakthrough alternative: tissue-engineered oral mucosa, that has the potential to eliminate the need for painful harvesting and enables scalable treatment for multiple indications.
Tissue-engineered, GMP-grade oral mucosa
Minimally invasive biopsy
Validated applications for urethral and ocular reconstruction
Autologous, scalable, and sustainable production process
What Sets Us Apart
Unlike traditional methods, our approach combines clinical validation with scalable production under GMP standards. This ensures both safety and accessibility for patients worldwide.
First scalable GMP process for oral mucosa replacement worldwide
Single-stage procedures with fast recovery times
Proven success rates with long-term follow-up
Independent GMP facility based in Bochum, Germany
Clinical Status
Our technology is not just a vision - it is already demonstrating favourable clinical results, and is on the path forward to regulatory approval.
Urethral Stricture
Our most advanced indication, showing strong outcomes and clear regulatory progress.
Phase II completed (app. 200 subjects, up to 60 month follow-up, favourable outcomes published)
Phase III underway with EMA/FDA endorsement
German sales approval expected in Q4/2025 (§ 4b AMG)
LSCD
(Limbal Stem Cell Deficiency)
A devastating cause of blindness, now with a clear therapeutic pathway.
Orphan Drug Designation (ODD) application submitted
Phase I/II clinical trials planned for 2026
ENT & Aesthetic Applications
Beyond urology and ophthalmology, we are developing new applications where tissue demand is high and donor tissue is limited.
Development in progress
Contact & Connect
We welcome inquiries from clinicians, researchers, and partners interested in shaping the future of tissue engineering with us.
Green Phoenix Labs GmbH
MukoCell®
Redefining Tissue Engineering for Real Lives
Our flagship product, MukoCell®, is the first scalable tissue-engineered oral mucosa graft. It is designed to replace painful harvesting techniques, accelerate recovery, and deliver reliable long-term outcomes for patients worldwide.